{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:47:12Z","timestamp":1792021632143,"version":"4.4.0"},"reference-count":70,"publisher":"Japanese Society of Internal Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,1,1]]},"DOI":"10.2169\/internalmedicine.5004-24","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T17:12:10Z","timestamp":1736874730000},"page":"23-31","source":"Crossref","is-referenced-by-count":8,"title":["Recent Advances and New Therapeutic Goals in the Management of Severe Asthma"],"prefix":"10.2169","volume":"65","author":[{"given":"Tomoya","family":"Harada","sequence":"first","affiliation":[{"name":"Division of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genki","family":"Inui","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Takata","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Okazaki","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Yamasaki","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Reports - Global Initiative for Asthma - GINA, 2024 [Internet]. [cited 2024 Jul 22]. Available from: https:\/\/ginasthma.org\/reports\/"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. Lancet 391: 783-800, 2018.","DOI":"10.1016\/S0140-6736(17)33311-1"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Hekking PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol 135: 896-902, 2015.","DOI":"10.1016\/j.jaci.2014.08.042"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Chastek B, Korrer S, Nagar SP, et al. Economic burden of illness among patients with severe asthma in a managed care setting. J Manag Care Spec Pharm 22: 848-861, 2016.","DOI":"10.18553\/jmcp.2016.22.7.848"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Nagase H, Adachi M, Matsunaga K, et al. Prevalence, disease burden, and treatment reality of patients with severe, uncontrolled asthma in Japan. Allergol Int 69: 53-60, 2020.","DOI":"10.1016\/j.alit.2019.06.003"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Sadatsafavi M, Lynd L, Marra C, et al. Direct health care costs associated with asthma in British Columbia. Can Respir J 17: 74-80, 2010.","DOI":"10.1155\/2010\/361071"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Shah PA, Brightling C. Biologics for severe asthma - Which, when and why? Respirology 28: 709-721, 2023.","DOI":"10.1111\/resp.14520"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Yamasaki A, Okazaki R, Harada T. Neutrophils and asthma. Diagnostics (Basel) 12: 1175, 2022.","DOI":"10.3390\/diagnostics12051175"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Nakamura Y, Tamaoki J, Nagase H, et al. Japanese guidelines for adult asthma 2020. Allergol Int 69: 519-548, 2020.","DOI":"10.1016\/j.alit.2020.08.001"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Schulman ES. Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders. Am J Respir Crit Care Med 164: S6-S11, 2001.","DOI":"10.1164\/ajrccm.164.supplement_1.2103025"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. MacGlashan DW Jr., Savage JH, Wood RA, Saini SS. Suppression of the basophil response to allergen during treatment with omalizumab is dependent on 2 competing factors. J Allergy Clin Immunol 130: 1130-1135.e1135, 2012.","DOI":"10.1016\/j.jaci.2012.05.038"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol 112: 1147-1154, 2003.","DOI":"10.1016\/j.jaci.2003.10.003"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60: 309-316, 2005.","DOI":"10.1111\/j.1398-9995.2004.00772.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Agache I, Rocha C, Beltran J, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: a systematic review for the EAACI guidelines - recommendations on the use of biologicals in severe asthma. Allergy 75: 1043-1057, 2020.","DOI":"10.1111\/all.14235"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Bousquet J, Humbert M, Gibson PG, et al. Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies. J Allergy Clin Immunol Pract 9: 2702-2714, 2021.","DOI":"10.1016\/j.jaip.2021.01.011"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Ohta K, Miyamoto T, Amagasaki T, Yamamoto M. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma. Respirology 14: 1156-1165, 2009.","DOI":"10.1111\/j.1440-1843.2009.01633.x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 154: 573-582, 2011.","DOI":"10.7326\/0003-4819-154-9-201105030-00002"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108: 184-190, 2001.","DOI":"10.1067\/mai.2001.117880"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 2014: CD003559, 2014.","DOI":"10.1002\/14651858.CD003559.pub4"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Hanania NA, Wenzel S, Ros\u00e9n K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 187: 804-811, 2013.","DOI":"10.1164\/rccm.201208-1414OC"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Casale TB, Chipps BE, Ros\u00e9n K, et al. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy 73: 490-497, 2018.","DOI":"10.1111\/all.13302"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Humbert M, Taille C, Mala L, et al. Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Eur Respir J 51: 1702523, 2018.","DOI":"10.1183\/13993003.02523-2017"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Casale TB, Luskin AT, Busse W, et al. Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study. J Allergy Clin Immunol Pract 7: 156-164.e151, 2019.","DOI":"10.1016\/j.jaip.2018.04.043"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Broughton SE, Nero TL, Dhagat U, et al. The \u03b2c receptor family - structural insights and their functional implications. Cytokine 74: 247-258, 2015.","DOI":"10.1016\/j.cyto.2015.02.005"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371: 1198-1207, 2014.","DOI":"10.1056\/NEJMoa1403290"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 371: 1189-1197, 2014.","DOI":"10.1056\/NEJMoa1403291"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med 5: 390-400, 2017.","DOI":"10.1016\/S2213-2600(17)30125-X"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Pilette C, Canonica GW, Chaudhuri R, et al. REALITI-A study: real-world oral corticosteroid-sparing effect of mepolizumab in severe asthma. J Allergy Clin Immunol Pract 10: 2646-2656, 2022.","DOI":"10.1016\/j.jaip.2022.05.042"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med 4: 549-556, 2016.","DOI":"10.1016\/S2213-2600(16)30031-5"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol 125: 1344-1353.e1342, 2010.","DOI":"10.1016\/j.jaci.2010.04.004"},{"key":"31","doi-asserted-by":"publisher","unstructured":"31. Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b2<sub>2<\/sub>-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 388: 2115-2127, 2016.","DOI":"10.1016\/S0140-6736(16)31324-1"},{"key":"32","doi-asserted-by":"publisher","unstructured":"32. FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 388: 2128-2141, 2016.","DOI":"10.1016\/S0140-6736(16)31322-8"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med 376: 2448-2458, 2017.","DOI":"10.1056\/NEJMoa1703501"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Menzies-Gow A, Gurnell M, Heaney LG, et al. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. Lancet Respir Med 10: 47-58, 2022.","DOI":"10.1016\/S2213-2600(21)00352-0"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Jackson DJ, Pelaia G, Emmanuel B, et al. Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme. Eur Respir J 64: 2301521, 2024.","DOI":"10.1183\/13993003.01521-2023"},{"key":"36","unstructured":"36. Harrison TW, Chanez P, Menzella F, et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respir Med 9: 260-274, 2021."},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. FitzGerald JM, Bleecker ER, Menzies-Gow A, et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med 6: 51-64, 2018.","DOI":"10.1016\/S2213-2600(17)30344-2"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Harb H, Chatila TA. Mechanisms of dupilumab. Clin Exp Allergy 50: 5-14, 2020.","DOI":"10.1111\/cea.13491"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 378: 2486-2496, 2018.","DOI":"10.1056\/NEJMoa1804092"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 378: 2475-2485, 2018.","DOI":"10.1056\/NEJMoa1804093"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Agache I, Song Y, Rocha C, et al. Efficacy and safety of treatment with dupilumab for severe asthma: a systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma. Allergy 75: 1058-1068, 2020.","DOI":"10.1111\/all.14268"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Blaiss M, Bleecker ER, Jacob-Nara J, et al. Real-world effectiveness of dupilumab in patients with asthma: findings from the US ADVANTAGE study. Ann Allergy Asthma Immunol 132: 463-468.e461, 2024.","DOI":"10.1016\/j.anai.2023.11.006"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Fukunaga K, Tagaya E, Ishida M, Sunaga Y, Koshiba R, Yokoyama A. Real-world impact of dupilumab on asthma disease burden in Japan: The CROSSROAD study. Allergol Int 72: 537-544, 2023.","DOI":"10.1016\/j.alit.2023.04.001"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Briegel I, Felicio-Briegel A, Mertsch P, Kneidinger N, Haubner F, Milger K. Hypereosinophilia with systemic manifestations under dupilumab and possibility of dual benralizumab and dupilumab therapy in patients with asthma and CRSwNP. J Allergy Clin Immunol Pract 9: 4477-4479, 2021.","DOI":"10.1016\/j.jaip.2021.07.049"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Zhou X, Yang G, Zeng X, et al. Dupilumab and the potential risk of eosinophilic pneumonia: case report, literature review, and FAERS database analysis. Front Immunol 14: 1277734, 2023.","DOI":"10.3389\/fimmu.2023.1277734"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Nakashima D, Mori E, Otori N. A case of recurrent chronic eosinophilic pneumonia after switching from benralizumab to dupilumab. Respir Med Case Rep 47: 101968, 2024.","DOI":"10.1016\/j.rmcr.2023.101968"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Roan F, Obata-Ninomiya K, Ziegler SF. Epithelial cell-derived cytokines: more than just signaling the alarm. J Clin Invest 129: 1441-1451, 2019.","DOI":"10.1172\/JCI124606"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med 384: 1800-1809, 2021.","DOI":"10.1056\/NEJMoa2034975"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Diver S, Khalfaoui L, Emson C, et al. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med 9: 1299-1312, 2021.","DOI":"10.1016\/S2213-2600(21)00226-5"},{"key":"50","unstructured":"50. Wechsler ME, Menzies-Gow A, Brightling CE, et al. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study. Lancet Respir Med 10: 650-660, 2022."},{"key":"51","unstructured":"51. Menzies-Gow A, Wechsler ME, Brightling CE, et al. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study. Lancet Respir Med 11: 425-438, 2023."},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ; The Group Health Medical Associates. Asthma and wheezing in the first six years of life. N Engl J Med 332: 133-138, 1995.","DOI":"10.1056\/NEJM199501193320301"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Sears MR, Greene JM, Willan AR, et al. A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. N Engl J Med 349: 1414-1422, 2003.","DOI":"10.1056\/NEJMoa022363"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Westerhof GA, Coumou H, de Nijs SB, Weersink EJ, Bel EH. Clinical predictors of remission and persistence of adult-onset asthma. J Allergy Clin Immunol 141: 104-109.e103, 2018.","DOI":"10.1016\/j.jaci.2017.03.034"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Maestrelli P. Natural history of adult-onset asthma: insights from model of occupational asthma. Am J Respir Crit Care Med 169: 331-332, 2004.","DOI":"10.1164\/rccm.2312012"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Menzies-Gow A, Bafadhel M, Busse WW, et al. An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol 145: 757-765, 2020.","DOI":"10.1016\/j.jaci.2019.12.006"},{"key":"57","unstructured":"57. Canonica GW, Blasi F, Carpagnano GE, et al. Severe asthma network Italy definition of clinical remission in severe asthma: a Delphi consensus. J Allergy Clin Immunol Pract 11: 3629-3637, 2023."},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Blaiss M, Oppenheimer J, Corbett M, et al. Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatment. Ann Allergy Asthma Immunol 131: 782-785, 2023.","DOI":"10.1016\/j.anai.2023.08.609"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Matsunaga K, Hamada K, Oishi K, Yano M, Yamaji Y, Hirano T. Factors associated with physician-patient discordance in the perception of asthma control. J Allergy Clin Immunol Pract 7: 2634-2641, 2019.","DOI":"10.1016\/j.jaip.2019.04.046"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Fuhlbrigge A, Marvel J, Electricwala B, et al. Physician-patient concordance in the assessment of asthma control. J Allergy Clin Immunol Pract 9: 3080-3088.e3081, 2021.","DOI":"10.1016\/j.jaip.2021.03.056"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Sullivan PW, Ghushchyan VH, Globe G, Schatz M. Oral corticosteroid exposure and adverse effects in asthmatic patients. J Allergy Clin Immunol 141: 110-116.e117, 2018.","DOI":"10.1016\/j.jaci.2017.04.009"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Dalal AA, Duh MS, Gozalo L, et al. Dose-response relationship between long-term systemic corticosteroid use and related complications in patients with severe asthma. J Manag Care Spec Pharm 22: 833-847, 2016.","DOI":"10.18553\/jmcp.2016.22.7.833"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Pavord I, Gardiner F, Heaney LG, et al. Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: analysis of the REDES study. Front Immunol 14: 1150162, 2023.","DOI":"10.3389\/fimmu.2023.1150162"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Perez-de-Llano L, Scelo G, Tran TN, et al. Exploring definitions and predictors of severe asthma clinical remission after biologic treatment in adults. Am J Respir Crit Care Med 210: 869-880, 2024.","DOI":"10.1164\/rccm.202311-2192OC"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Pavord ID, Rabe KF, Israel E, et al. Dupilumab induces long-term on-treatment clinical remission in patients with type 2 asthma. J Allergy Clin Immunol Pract 13: 132-142, 2025.","DOI":"10.1016\/j.jaip.2024.10.009"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Ledford D, Busse W, Trzaskoma B, et al. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. J Allergy Clin Immunol 140: 162-169.e2, 2017.","DOI":"10.1016\/j.jaci.2016.08.054"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Moore WC, Kornmann O, Humbert M, et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). Eur Respir J 59: 2100396, 2022.","DOI":"10.1183\/13993003.00396-2021"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Ortega H, Lemiere C, Llanos JP, et al. Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial. Allergy Asthma Clin Immunol 15: 37, 2019.","DOI":"10.1186\/s13223-019-0348-z"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Kelsen SG, Agache IO, Soong W, et al. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial. J Allergy Clin Immunol 148: 790-798, 2021.","DOI":"10.1016\/j.jaci.2021.03.044"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Okazaki R, Harada T, Funaki Y, et al. Efficacy, safety, and continuation of biological therapy in older patients with asthma in a real-world setting: a retrospective observational study. Yonago Acta Med 67: 114-123, 2024.","DOI":"10.33160\/yam.2024.05.003"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/1\/65_5004-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T03:26:39Z","timestamp":1767410799000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/1\/65_5004-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5004-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"article-number":"5004-24"}}